{"id":955232,"date":"2026-04-28T07:06:49","date_gmt":"2026-04-28T11:06:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/"},"modified":"2026-04-28T07:06:49","modified_gmt":"2026-04-28T11:06:49","slug":"ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/","title":{"rendered":"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., April  28, 2026  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.<\/p>\n<p>\n        <strong>Conference Call and Webcast Information<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p>Date: Tuesday, May 5, 2026 at 8:00 AM ET<br \/>Participant Dial-In (U.S.): 1-800-343-4136<br \/>Participant Dial-In (International): 1-203-518-9843<br \/>Conference ID: OCULAR (required for entry)<br \/>Webcast Access: Please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oI_VVIMGVyi5g_jHnjf_fr-r_YE6IApw0ihS6m3DKIb8_xlIhutfPWa5Mau_7iIvHjxPlen_t17mi5TKJIqxRMgsO9zVNY0M73nr22gGenxFU09SbiNidXfe_njqXZwcHd_XAgYw-G5bDBfSHil9Cw==\" rel=\"nofollow\" target=\"_blank\">here<\/a><\/p>\n<p>The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.<\/p>\n<p>\n        <strong>About Ocular Therapeutix, Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.<\/p>\n<p>Follow the Company on its website, LinkedIn, or X.<\/p>\n<p>DEXTENZA<sup>\u00ae<\/sup> is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gEtD2ZpOnppBtXMryfOKOplap3anYhLo77c217nClqKVTMZC-X8jRnweWbdiyIHAmsR-o_lkmFUHZJWzD7CG7pos-IxeMQfPNwdXPuGg8kw=\" rel=\"nofollow\" target=\"_blank\">bslattery@ocutx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTQ2MjMzNTctYmU1MS00M2Q5LWIwYzYtMDcxNTliMDI1NzYxLTEwMjI2MjktMjAyNi0wNC0yOC1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information : Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U.S.): 1-800-343-4136Participant Dial-In (International): 1-203-518-9843Conference ID: OCULAR (required for entry)Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955232","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information : Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U.S.): 1-800-343-4136Participant Dial-In (International): 1-203-518-9843Conference ID: OCULAR (required for entry)Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T11:06:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026\",\"datePublished\":\"2026-04-28T11:06:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/\"},\"wordCount\":342,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=\",\"datePublished\":\"2026-04-28T11:06:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026 - Market Newsdesk","og_description":"BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information : Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U.S.): 1-800-343-4136Participant Dial-In (International): 1-203-518-9843Conference ID: OCULAR (required for entry)Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of &hellip; Continue reading \"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-28T11:06:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026","datePublished":"2026-04-28T11:06:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/"},"wordCount":342,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/","name":"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=","datePublished":"2026-04-28T11:06:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwODAyNiM3NTY5MDY0IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-report-first-quarter-2026-financial-results-on-may-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Report First Quarter 2026 Financial Results on May 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955232"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955232\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}